tiprankstipranks
Advertisement
Advertisement

KLRS Stock Latest News

Kalaris Therapeutics reports Q2 EPS (48c), consensus (50c)
The FlyKalaris Therapeutics reports Q2 EPS (48c), consensus (50c)
24d ago
KLRS
Kalaris Therapeutics Strengthens Financial Leadership With New CFO
PremiumCompany Announcements
Kalaris Therapeutics Strengthens Financial Leadership With New CFO
2M ago
8K
KLRS
Kalaris Therapeutics appoints Liisa Bayko as CFO
PremiumThe Fly
Kalaris Therapeutics appoints Liisa Bayko as CFO
2M ago
KLRS
Judah Frommer Maintains Buy on KLRS as TH103 Data Strengthen Risk‑Reward, Keeps Price Target Unchanged at $14
PremiumRatings
Judah Frommer Maintains Buy on KLRS as TH103 Data Strengthen Risk‑Reward, Keeps Price Target Unchanged at $14
2M ago
KLRS
Why Is Kalaris Therapeutics (KLRS) Up Today?
PremiumMarket News
Why Is Kalaris Therapeutics (KLRS) Up Today?
2M ago
KLRS
Analyst Maintains Buy on KLRS as TH103’s Emerging nAMD Data Highlight Rapid Efficacy and Differentiated Durability
PremiumRatingsAnalyst Maintains Buy on KLRS as TH103’s Emerging nAMD Data Highlight Rapid Efficacy and Differentiated Durability
2M ago
KLRS
Kalaris Therapeutics reports positive Phase 1a TH103 results
Premium
Company Announcements
Kalaris Therapeutics reports positive Phase 1a TH103 results
2M ago
8K
KLRS
Kalaris Therapeutics reports additional data from ascending dose trial of TH103
Premium
The Fly
Kalaris Therapeutics reports additional data from ascending dose trial of TH103
2M ago
KLRS
Kalaris Therapeutics Announces Board and Audit Committee Changes
PremiumCompany Announcements
Kalaris Therapeutics Announces Board and Audit Committee Changes
2M ago
8K
KLRS
Kalaris Therapeutics initiated with a Buy at TD Cowen
PremiumThe Fly
Kalaris Therapeutics initiated with a Buy at TD Cowen
3M ago
KLRS
Tara Bancroft Initiates Buy on TH103 Developer, Citing Differentiated Wet AMD Profile and Strong Durability Potential in $15B Anti‑VEGF Market
PremiumRatings
Tara Bancroft Initiates Buy on TH103 Developer, Citing Differentiated Wet AMD Profile and Strong Durability Potential in $15B Anti‑VEGF Market
3M ago
KLRS
Kalaris Therapeutics Shareholders Back Board, Pay and Auditor
PremiumCompany Announcements
Kalaris Therapeutics Shareholders Back Board, Pay and Auditor
3M ago
8K
KLRS
CRWV, CVBF, KLRS — Insiders Are Buying These 3 Stocks
PremiumMarket NewsCRWV, CVBF, KLRS — Insiders Are Buying These 3 Stocks
3M ago
CRWV
CVBF
Kalaris Therapeutics, Inc. (KLRS) Q1 Earnings Cheat Sheet
Premium
Pre-Earnings
Kalaris Therapeutics, Inc. (KLRS) Q1 Earnings Cheat Sheet
4M ago
KLRS
Starbucks upgraded, Doximity downgraded: Wall Street’s top analyst calls
Premium
The Fly
Starbucks upgraded, Doximity downgraded: Wall Street’s top analyst calls
4M ago
TM
AIZ
Wedbush bullish on Kalaris Therapeutics, initiates with an Outperform
PremiumThe Fly
Wedbush bullish on Kalaris Therapeutics, initiates with an Outperform
4M ago
KLRS
Kalaris Therapeutics initiated with an Outperform at Wedbush
PremiumThe Fly
Kalaris Therapeutics initiated with an Outperform at Wedbush
4M ago
KLRS
Kalaris Therapeutics price target lowered to $25 from $26 at Citizens
PremiumThe Fly
Kalaris Therapeutics price target lowered to $25 from $26 at Citizens
4M ago
KLRS
Kalaris Therapeutics reports Q1 EPS (46c), consensus (52c)
PremiumThe Fly
Kalaris Therapeutics reports Q1 EPS (46c), consensus (52c)
4M ago
KLRS
Kalaris Therapeutics initiated with an Overweight at Morgan Stanley
PremiumThe FlyKalaris Therapeutics initiated with an Overweight at Morgan Stanley
5M ago
KLRS
Kalaris Therapeutics Announces CFO Resignation, Finance Leadership Shift
Premium
Company Announcements
Kalaris Therapeutics Announces CFO Resignation, Finance Leadership Shift
5M ago
8K
KLRS
Kalaris Therapeutics: Early TH103 Data in nAMD Support Buy Rating and Favorable Risk/Reward Despite Manufacturing Hurdles
Premium
Ratings
Kalaris Therapeutics: Early TH103 Data in nAMD Support Buy Rating and Favorable Risk/Reward Despite Manufacturing Hurdles
6M ago
KLRS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >